Analysts Set Certara, Inc. (NASDAQ:CERT) Target Price at $17.08

Certara, Inc. (NASDAQ:CERT - Get Free Report) has been assigned a consensus rating of "Hold" from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $17.08.

Several brokerages recently issued reports on CERT. JMP Securities reiterated a "market perform" rating on shares of Certara in a report on Wednesday, July 10th. KeyCorp lowered their price objective on shares of Certara from $23.00 to $20.00 and set an "overweight" rating for the company in a research report on Thursday, July 11th. UBS Group raised shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a report on Friday, September 27th. Barclays lowered their target price on Certara from $16.00 to $14.00 and set an "equal weight" rating on the stock in a research report on Tuesday. Finally, Robert W. Baird decreased their price objective on shares of Certara from $19.00 to $18.00 and set a "neutral" rating for the company in a report on Wednesday, August 7th.

Certara Stock Up 3.1 %

Shares of Certara stock traded up $0.35 during trading hours on Thursday, hitting $11.57. The company had a trading volume of 1,956,591 shares, compared to its average volume of 754,031. The company's 50-day moving average is $11.67 and its two-hundred day moving average is $14.48. The company has a market cap of $1.86 billion, a P/E ratio of -28.77, a price-to-earnings-growth ratio of 5.40 and a beta of 1.49. Certara has a twelve month low of $10.35 and a twelve month high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business's revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period last year, the company earned $0.10 earnings per share. Analysts anticipate that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Leif E. Pedersen sold 51,224 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.39% of the company's stock.

Institutional Trading of Certara

Hedge funds have recently added to or reduced their stakes in the company. First Hawaiian Bank bought a new position in Certara in the first quarter valued at approximately $618,000. Wasatch Advisors LP increased its stake in shares of Certara by 23.4% in the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company's stock valued at $88,056,000 after acquiring an additional 932,598 shares in the last quarter. Capstone Investment Advisors LLC acquired a new position in shares of Certara during the first quarter worth approximately $245,000. GSA Capital Partners LLP purchased a new position in shares of Certara during the first quarter valued at approximately $571,000. Finally, Geneva Capital Management LLC grew its position in Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company's stock worth $78,747,000 after purchasing an additional 579,349 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.